Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Valneva SE, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 15
Private Equity 16
Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16
Partnerships 17
InFlectis BioScience Enters into Licensing Agreement with Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 18
Valneva Enters into R&D Agreement with GlaxoSmithKline 19
Valneva Enters into Distribution Agreement with PaxVax 20
PaxVax Enters into Distribution Agreement with Valneva 21
Valneva Forms Joint Venture with BliNK Therapeutics 22
Licensing Agreements 23
Emergent BioSolutions Enters into Licensing Agreement with Valneva 23
Bavarian Nordic Enters into Licensing Agreement with Valneva 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 25
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28
Valneva to Enter into Licensing Agreement with Pharma Company 29
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30
GeoVax Labs Enters into Licensing Agreement with Valneva 31
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32
Equity Offering 33
Valneva Raises USD54 Million in Rights Offering 33
Valneva Completes Rights Offering Of Shares For US$53.5 Million 35
Asset Transactions 37
Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37
Acquisition 38
Valneva Acquires Crucell Sweden for USD54 Million 38
Valneva SE – Key Competitors 39
Valneva SE – Key Employees 40
Valneva SE – Locations And Subsidiaries 41
Head Office 41
Other Locations & Subsidiaries 41
Recent Developments 43
Financial Announcements 43
Aug 02, 2018: VALNEVA Delivers Strong IXIARO Sales Growth and reports Further Progress on Key R&D Programs in H1 43
May 17, 2018: VALNEVA Reports Strong Q1 Results and Continues to Advance Key R&D Programs 47
Mar 22, 2018: VALNEVA Delivers Strong 2017 Financial Results and Advances Key R&D Programs 50
Nov 09, 2017: Valneva Reports Strong Operational Performance for the First Nine Months of 2017 54
Aug 31, 2017: Valneva Reports Robust H1 2017 Financial Results & Major R&D Progress 55
May 11, 2017: VALNEVA Reports Strong Q1 Revenue Growth and Positive EBITDA; Reaffirms Financial Guidance and Pipeline Outlook for 2017 60
Mar 23, 2017: VALNEVA Reports Best Financial Results in the Company’s History with its First Year of Positive EBITDA in 2016 63
Feb 23, 2017: VALNEVA Reports Strong Q4 and FY 2016 Business Performance; Expects Further Growth in Sales and EBITDA, R&D Progress in 2017 68
Corporate Communications 71
Jun 29, 2018: VALNEVA Announces Successful Outcome of its AGM and Renewal of the Term of Office of its Management Board Members 71
Aug 01, 2017: VALNEVA Announces Expansion of its Management Board – Strengthening Senior Management for Future Growth 72
Product News 73
Apr 10, 2017: Valneva to Present at the 17th World Vaccine Congress in Washington D.C. 73
Clinical Trials 74
Mar 29, 2018: VALNEVA to Present Data on VLA-1601 at the 18th World Vaccine Congress in Washington, D.C. 74
Feb 26, 2018: Emergent BioSolutions and Valneva Initiate Phase 1 Clinical Study to Evaluate Vaccine Candidate Against Zika Virus 75
Other Significant Developments 76
Sep 20, 2018: Valneva announces extension of drawdown period for its existing european investment bank loan 76
Dec 11, 2017: Intercell USA Changes Name to Valneva USA and Expands Commercial Presence 77
Jun 30, 2017: Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members 78
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
Valneva SE, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10
Valneva SE, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Valneva to Secure USD18 Million from Funds Managed by Athyrium 13
BliNK Biomedical Raises Funds through Series A Venture Financing 14
Valneva Austria Raises US$30 Million In Venture Financing 15
Valneva Raises USD8 Million in First Tranche of Private Equity Investment 16
InFlectis BioScience Enters into Licensing Agreement with Valneva 17
Seqirus Enters into Distribution Agreement with Valneva 18
Valneva Enters into R&D Agreement with GlaxoSmithKline 19
Valneva Enters into Distribution Agreement with PaxVax 20
PaxVax Enters into Distribution Agreement with Valneva 21
Valneva Forms Joint Venture with BliNK Therapeutics 22
Emergent BioSolutions Enters into Licensing Agreement with Valneva 23
Bavarian Nordic Enters into Licensing Agreement with Valneva 24
Valneva Enters into Licensing Agreement with Jianshun Biosciences 25
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 26
Valneva Enters into Licensing Agreement with Adimmune for Japanese Encephalitis Vaccine 27
Valneva Enters into Research Licensing Agreement with Emergent BioSolutions for EB66 Cell Line 28
Valneva to Enter into Licensing Agreement with Pharma Company 29
Valneva to Enter into Licensing Agreement with Japan-Based Animal Vaccine Manufacturer 30
GeoVax Labs Enters into Licensing Agreement with Valneva 31
Valneva Enters Into Licensing Agreement With International AIDS Vaccine Initiative For HIV Vaccine 32
Valneva Raises USD54 Million in Rights Offering 33
Valneva Completes Rights Offering Of Shares For US$53.5 Million 35
Valneva Sells Clinical Manufacturing Operations Facility To Biological E 37
Valneva Acquires Crucell Sweden for USD54 Million 38
Valneva SE, Key Competitors 39
Valneva SE, Key Employees 40
Valneva SE, Other Locations 41
Valneva SE, Subsidiaries 41
List of Figures
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Valneva SE, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Valneva SE, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Valneva SE, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Valneva SE, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Valneva SE, Medical Devices Deals, 2012 to YTD 2018 10